Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIACI of Cetuximab and Bevacizumab for Pediatric Glioma
NCT01884740Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2013
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, bevacizumab in glioma, sponsored by Weill Cornell Medicine. Started Jun 2013; status: terminated.
02
Drugs
KL-140bevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT01884740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01884740.